genentech cancer immunology：In situ tumour arrays reveal early environmental control of ...
In situ tumour arrays reveal early environmental control of ...
由GOrtiz-Muñoz著作·2023·被引用16次—KPP(PDAC)andNSCLCcellswerederivedfromprimarytumoursofGenentechCancerImmunologyGEMMmice....Elementsofcancerimmunityandthe ...。其他文章還包含有：「Topics」、「Oncology&CancerImmunotherapy」、「IraMellman」、「CancerImmunology」、「AkshayKrishnamurty」、「RosaBarreiradaSilva」、「Thecancerimmunitycycle」、「IraMellman」、「2023SITC」
查看更多 離開網站
Topics
https://www.gene.com
A new framework for cancer immunotherapy research around the world.
Oncology & Cancer Immunotherapy
https://www.gene.com
Oncology & Cancer Immunotherapy. Our ultimate vision is to prevent and provide cures for cancer in all its forms. Because no single intervention is likely ...
Ira Mellman
https://www.gene.com
I believe in allowing people to grow and think for themselves, to learn how to frame problems and to plot the best paths to answer them. These are scientific ...
Cancer Immunology
https://www.genentech-medinfo.
Cancer-Immunity Cycle. The genetic and cellular alterations that characterize cancer cells can be recognized by the immune system as foreign, resulting in T ...
Akshay Krishnamurty
https://www.gene.com
My career at Genentech began in 2017 as a postdoctoral fellow in the Cancer Immunology department studying the cellular complexity of tumors.
Rosa Barreira da Silva
https://www.gene.com
It is extremely exciting to be working at the forefront of cancer immunotherapy research in such a vibrant and collaborative scientific community as Genentech..
The cancer immunity cycle
https://www.roche.com
A new framework is redefining how we implement personalised cancer immunotherapy research around the world.
Ira Mellman
https://www.linkedin.com
Experience. Genentech Graphic. Vice President of Cancer Immunology. Genentech. Apr 2007 - Present 17 years 5 months. South San Francisco, California, ...
2023 SITC
https://www.sitcancer.org
This $100,000, one-year cancer immunotherapy fellowship helps support the development of a female immunotherapy expert who has an MD, a PhD or a combined MD/PhD ...